Andrew Almonte is a postdoctoral researcher in Laurence Zitvogel’s laboratory at Gustave Roussy in Paris, where he studies interactions between the gut microbiome, adaptive immunity, and cancer immunotherapy. His work focuses on how host antibody responses to intestinal bacteria shape microbiome–immune relationships and influence responses to immune checkpoint blockade. His research combines clinical cohorts, microbiome profiling, flow cytometry, mouse models, and computational analysis. A central aim is to understand how faecal microbiota transplantation and other microbiome-centred interventions remodel host–microbiome immune interactions, with the goal of developing mechanistically grounded biomarkers and strategies to improve immunotherapy. Andrew holds a Bachelor of Science from the United States Naval Academy, and a Master of Biological Sciences (Advanced) and Doctor of Philosophy from the Australian National University. Before joining Gustave Roussy, he worked in the Mark Davis and Yueh-Hsiu Chien laboratories at Stanford University School of Medicine while completing his doctorate. His doctoral research centred on bacteria-based cancer immunotherapy and the gut microbiome’s influence on immune checkpoint blockade.